Gait dysfunction in Alzheimer disease

Handb Clin Neurol. 2023:196:267-274. doi: 10.1016/B978-0-323-98817-9.00013-2.


Alzheimer's disease (AD) is the most common cause of age-associated dementia and will exponentially rise in prevalence in the coming decades, supporting the parallel development of the early stage detection and disease-modifying strategies. While primarily considered as a cognitive disorder, AD also features motor symptoms, primarily gait dysfunction. Such gait abnormalities can be phenotyped across classic clinical syndromes as well as by quantitative kinematic assessments to address subtle dysfunction at preclinical and prodromal stages. As such, certain measures of gait can predict the future cognitive and functional decline. Moreover, cross-sectional and longitudinal studies have associated gait abnormalities with imaging, biofluid, and genetic markers of AD across all stages. This suggests that gait assessment is an important tool in the clinical assessment of patients across the AD spectrum, especially to help identify at-risk individuals.

Keywords: Alzheimer disease; Amyloid; Biomarkers; Clinical syndromes; Gait; Motor disorders.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / complications
  • Cognition Disorders*
  • Cognitive Dysfunction*
  • Cross-Sectional Studies
  • Gait
  • Humans